---
title: A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
nct_id: NCT05852769
overall_status: COMPLETED
phase: PHASE1
sponsor: Bristol-Myers Squibb
study_type: INTERVENTIONAL
primary_condition: Healthy Volunteers
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05852769.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05852769"
ct_last_update_post_date: 2023-09-26
last_seen_at: "2026-05-12T07:05:14.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

**Official Title:** A Phase 1, Single-center, Open-label, Sequential Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

**NCT ID:** [NCT05852769](https://clinicaltrials.gov/study/NCT05852769)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 18
- **Lead Sponsor:** Bristol-Myers Squibb
- **Conditions:** Healthy Volunteers
- **Start Date:** 2023-05-31
- **Completion Date:** 2023-08-24
- **CT.gov Last Update:** 2023-09-26

## Brief Summary

This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 55 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations.
* Body mass index of 18.0 to 33.0 kilogram per meter squared (kg/m\^2), inclusive, and body weight ≥50.0 kg.

Exclusion Criteria:

* History of rhabdomyolysis.
* History of peptic ulcer disease or significant GI bleeding.
* History of malignancy in the 5 years prior to screening (except fully excised basal cell carcinoma).
```

## Arms

- **BMS-986196 and/or Cocktail Probe Substrate Drugs** (EXPERIMENTAL)

## Interventions

- **BMS-986196** (DRUG) — Specified dose on specified days
- **Caffeine** (DRUG) — Specified dose on specified days
- **Montelukast** (DRUG) — Specified dose on specified days
- **Flurbiprofen** (DRUG) — Specified dose on specified days
- **Omeprazole** (DRUG) — Specified dose on specified days
- **Midazolam** (DRUG) — Specified dose on specified days
- **Digoxin** (DRUG) — Specified dose on specified days
- **Pravastatin** (DRUG) — Specified dose on specified days

## Primary Outcomes

- **Maximum observed plasma concentration (Cmax)** _(time frame: Up to 26 days)_
- **Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])** _(time frame: Up to 26 days)_
- **Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC[0-T])** _(time frame: Up to 26 days)_

## Secondary Outcomes

- **Time of maximum observed serum concentration (Tmax)** _(time frame: Up to 26 days)_
- **Apparent terminal phase half-life (T-Half)** _(time frame: Up to 26 days)_
- **Apparent total body clearance (CLT/F)** _(time frame: Up to 26 days)_
- **Number of participants with adverse events (AEs)** _(time frame: Up to 52 days)_
- **Number of participants with vital sign abnormalities** _(time frame: Up to 28 days)_
- **Number of participants with electrocardiogram (ECG) abnormalities** _(time frame: Up to 21 days)_
- **Number of participants with physical examination abnormalities** _(time frame: Up to 28 days)_
- **Number of participants with clinical laboratory abnormalities** _(time frame: Up to 28 days)_
- **Intensity of Suicidal Ideation as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) Score** _(time frame: Up to 28 days)_

## Locations (1)

- ICON plc, Millcreek, Utah, United States

## Recent Field Changes (last 30 days)

- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `locations.icon plc|millcreek|utah|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05852769.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05852769*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*